CeNeRx (Cary, NC) a clinical-stage biopharmaceutical company focused on diseases of the central nervous system, closed a $10M Series C, bringing the round total to $14M. Participants include Aisling Capital, L Capital Partners and Pappas Ventures.

TPP Global Development (United Kingdom) a preclinical-stage drug development company focused on acquiring and developing early-stage intellectual property in the CNS, inflammation and oncology sectors, closed a $12.2M Series A financing. Participants include Scottish Venture Fund.

NeuroTherapeutics Pharma (Chicago, IL) a clinical-stage biopharmaceutical company focused on the CNS disorders of epilepsy, acute and neuropathic pain, closed a $43M Series B financing. Participants include Fidelity Biosciences, MPM Capital, S.R. One, Pfizer, Novo Ventures and Thomas McNerney & Partners.

Adamas Pharmaceuticals (Emeryville, CA) a development-stage small molecule company focused on neurological (Parkinson’s and dementia) and infectious (influenza) diseases, closed a $40M Series D financing. Participants include Aeris Capital, DAG Ventures, Mohr Davidow Ventures and Northgate Capital.

Curemark (Rye, NY) a clinical-stage biopharma company focused on the treatment of neurological disease (autism and ADHD), clased a $6.5M Series A financing. Participants were not disclosed.

Helicon Therapeutics (San Diego, CA) a clinical-stage biotech focused on the development of modulating memory formation from short-term memories, and the conversion of short-term memory to long-term memory, closed a $50M Series F financing. Participants in the round were not named

CeNeRx BioPharma (Cary, NC) a clinical-stage biopharmaceutical company focused on diseases of the central nervous system, closed a $4M Series C financing. Participants include Aisling Capital, L Capital Partners and Pappas Ventures.

Marinus Pharmaceuticals (Branford, CT) a clinical-stage company focused on reformulation and development of therapeutics for the treatment of CNS, psychiatric and pain disorders, closed a $20M Series B financing. Participants include Canaan Partners, Domain Associates, Sofinnova Ventures and Foundation Medical Partners.

KeyNeurotek Pharmaceuticals (Germany) a clinical-stage small molecule company focused on autoimmune and CNS diseases, closed a $10.9M Series C financing. Participants include DVC Deutsche Venture Capital, IBG Beteiligungsgesellschaft and KfW Bankengruppe.

Mithridion (Madison, WI) an early-stage drug development company focused on central nervous system disorders, including Alzheimer’s disease, closed a $2.9M Series B financing. Participants include Venture Investors, Rocket Ventures, The State of Wisconsin Investment Board and Wisconsin Investment Partners.